Brokerages Set Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Price Target at $61.33

Shares of Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) have earned a consensus rating of “Buy” from the seven analysts that are covering the firm, Marketbeat.com reports. Seven analysts have rated the stock with a buy recommendation. The average 12-month price objective among brokerages that have issued a report on the stock in the last year is $61.33.

Several research firms have weighed in on ARCT. HC Wainwright reiterated a “buy” rating and issued a $60.00 price objective on shares of Arcturus Therapeutics in a report on Wednesday, March 20th. William Blair reiterated an “outperform” rating on shares of Arcturus Therapeutics in a report on Friday, March 8th. Finally, Citigroup boosted their price objective on shares of Arcturus Therapeutics from $40.00 to $48.00 and gave the company a “buy” rating in a research report on Thursday, February 8th.

Insider Transactions at Arcturus Therapeutics

In other news, COO Pad Chivukula sold 17,435 shares of the company’s stock in a transaction on Monday, March 25th. The stock was sold at an average price of $35.02, for a total value of $610,573.70. Following the completion of the sale, the chief operating officer now directly owns 473,448 shares in the company, valued at approximately $16,580,148.96. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Company insiders own 13.80% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Assenagon Asset Management S.A. purchased a new position in Arcturus Therapeutics during the first quarter valued at $1,865,000. Denali Advisors LLC bought a new position in shares of Arcturus Therapeutics during the 1st quarter valued at approximately $209,000. Hennion & Walsh Asset Management Inc. raised its stake in Arcturus Therapeutics by 2.5% during the first quarter. Hennion & Walsh Asset Management Inc. now owns 31,930 shares of the biotechnology company’s stock valued at $1,078,000 after purchasing an additional 778 shares in the last quarter. Wellington Management Group LLP grew its stake in shares of Arcturus Therapeutics by 40.3% in the 4th quarter. Wellington Management Group LLP now owns 60,841 shares of the biotechnology company’s stock worth $1,918,000 after buying an additional 17,491 shares in the last quarter. Finally, Public Employees Retirement System of Ohio purchased a new stake in shares of Arcturus Therapeutics during the 4th quarter valued at about $89,000. 94.54% of the stock is currently owned by institutional investors.

Arcturus Therapeutics Stock Down 3.0 %

Shares of NASDAQ ARCT opened at $26.17 on Friday. The company has a market cap of $704.50 million, a price-to-earnings ratio of -25.16 and a beta of 2.60. The firm’s fifty day moving average is $33.94 and its 200 day moving average is $29.79. Arcturus Therapeutics has a 52 week low of $17.52 and a 52 week high of $43.81.

Arcturus Therapeutics (NASDAQ:ARCT) last released its quarterly earnings data on Thursday, March 7th. The biotechnology company reported ($0.32) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.69) by $1.37. The firm had revenue of $33.99 million for the quarter, compared to analysts’ expectations of $64.14 million. Arcturus Therapeutics had a negative net margin of 15.65% and a negative return on equity of 18.22%. Equities research analysts anticipate that Arcturus Therapeutics will post -2.83 earnings per share for the current year.

About Arcturus Therapeutics

Arcturus Therapeutics Holdings Inc, a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA.